09.01.2014 09:33
Bewerten
(0)

Press Release: BioCrea Wins The Epilepsy Innovation Seal of Excellence Award

BioCrea / BioCrea Wins The Epilepsy Innovation Seal of Excellence Award . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Radebeul, Germany, January 9, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist validated through pharma partnerships, announced today that the Epilepsy Foundation (Maryland, US) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, Novel Long Term Effective GABA(A) PAMs (LT GABA(A) PAM), to treat refractory epilepsy.

"We are delighted to receive the prestigious SEAL award," said Dr. Tom Kronbach, CEO of BioCrea. "This recognition by the Epilepsy Foundation for our work on the LT GABA(A) PAM platform is highly appreciated. We are impressed that the Foundation's Scientific Advisory Board and Business Advisory Board do see the potential for our platform to deliver efficacious and novel epilepsy treatments which are currently at candidate selection stage. Having successfully delivered novel treatments for partners such as Pfizer, GlaxoSmithKline, Wyeth and Boehringer Ingelheim, we are well placed to further build our portfolio of projects."

The Epilepsy Foundation stated in a letter to BioCrea: "This award is based on the enthusiasm of the Epilepsy Foundation's Scientific Advisory Broad and Business Advisory Board for the present accomplishments and future potential of this new drug platform that we hope will alleviate the suffering of persons with epilepsy."

About BioCrea

BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). BioCrea was awarded Top Innovator status of the "Top 100" Most Innovative Companies in Germany 2012 by compamedia GmbH.

About the Epilepsy Foundation

The Epilepsy Foundation, a national non-profit with 47 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The Foundation works to prevent, control and cure epilepsy through community services; public education; federal and local advocacy; and supporting research into new treatments and therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit: www.epilepsy.com.

Contact

Dr. Tom Kronbach

CEO, BioCrea GmbH

Tel.: +49 351 / 4043 3332

Fax: +49 351 / 4043 3216

tom.kronbach@biocrea.com

Press Release PDF: http://hugin.info/156612/R/1753539/591527.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BioCrea via Globenewswire

HUG#1753539

--- End of Message ---

BioCrea

BioCrea GmbH Radebeul Germany

http://www.biocrea.com (END) Dow Jones Newswires

   January 09, 2014 03:00 ET (08:00 GMT)- - 03 00 AM EST 01-09-14

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Stabile Dividendenaktien gehören in jedes Depot!

Die Investition in ausgewählte Blue-Chip-Dividendenaktien gehört zu den sichersten Strategien, um an den Aktienmärkten langfristig ein Vermögen aufzubauen. Dividendenaktien von hochkapitalisierten Unternehmen werfen langfristig höhere Renditen als der Gesamtmarkt ab und bieten einen guten Schutz in unsicheren Börsenzeiten. Wir stellen im aktuellen Anlegermagazin drei Aktien mit stabilen und attraktiven Dividendenrenditen vor.
Anlegermagazin kostenlos erhalten

Heute im Fokus

DAX schließt fester -- Dow Jones am Ende nahezu unverändert -- Takata-Aktie im freien Fall: Insolvenzantrag steht kurz bevor -- AURELIUS verspricht mehr Transparenz -- METRO, Oracle im Fokus

Übernahmeziel Pfeiffer Vacuum kauft in den USA selbst zu. Tesla überholt BMW. E-Autos: Mit diesen sechs Aktien sind Anleger für die Zukunft der Mobilität gerüstet. Interpol fahndet wohl nach VW-Managern wegen Dieselbetrugs. Ölpreise nach jüngstem Preissturz etwas gestiegen. EU genehmigt Evonik Übernahme von Huber Silica. Apple will Musikkonzernen offenbar weniger zahlen. Kepler hält E.ON für zu teuer und rät zum Verkauf.

Top-Rankings

In diese Unternehmen investiert Amazon
Welche Unternehmen profitieren von Jeff Bezos?
KW 24: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten
KW 24: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten

Umfrage

Wenn morgen Bundestagswahl wäre, wen würden Sie wählen?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Nordex AGA0D655
Volkswagen (VW) AG Vz.766403
Apple Inc.865985
CommerzbankCBK100
AURELIUSA0JK2A
TeslaA1CX3T
EVOTEC AG566480
E.ON SEENAG99
AMD (Advanced Micro Devices) Inc.863186
Amazon.com Inc.906866
Deutsche Telekom AG555750
BMW AG519000
Allianz840400